Sculptor Capital LP Boosts Stake in Haleon PLC Sponsored ADR $HLN

Sculptor Capital LP raised its position in shares of Haleon PLC Sponsored ADR (NYSE:HLN) by 5.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 10,454,868 shares of the company’s stock after acquiring an additional 505,000 shares during the period. Haleon makes up 1.1% of Sculptor Capital LP’s portfolio, making the stock its 19th biggest position. Sculptor Capital LP’s holdings in Haleon were worth $105,699,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the company. National Bank of Canada FI grew its position in Haleon by 6.7% during the third quarter. National Bank of Canada FI now owns 17,385 shares of the company’s stock valued at $156,000 after acquiring an additional 1,099 shares during the period. Oppenheimer & Co. Inc. grew its position in Haleon by 4.7% during the fourth quarter. Oppenheimer & Co. Inc. now owns 24,744 shares of the company’s stock valued at $250,000 after acquiring an additional 1,100 shares during the period. Cary Street Partners Financial LLC grew its position in Haleon by 20.1% during the second quarter. Cary Street Partners Financial LLC now owns 6,646 shares of the company’s stock valued at $69,000 after acquiring an additional 1,113 shares during the period. Advisory Services Network LLC grew its position in Haleon by 7.1% during the third quarter. Advisory Services Network LLC now owns 17,431 shares of the company’s stock valued at $156,000 after acquiring an additional 1,155 shares during the period. Finally, Geneos Wealth Management Inc. grew its position in Haleon by 33.0% during the first quarter. Geneos Wealth Management Inc. now owns 4,846 shares of the company’s stock valued at $50,000 after acquiring an additional 1,203 shares during the period. Hedge funds and other institutional investors own 6.67% of the company’s stock.

Haleon Price Performance

Shares of NYSE HLN opened at $9.08 on Tuesday. Haleon PLC Sponsored ADR has a 1-year low of $8.65 and a 1-year high of $11.28. The business has a 50-day moving average of $9.33 and a 200-day moving average of $9.90. The company has a debt-to-equity ratio of 0.47, a current ratio of 0.92 and a quick ratio of 0.71. The company has a market capitalization of $40.14 billion, a price-to-earnings ratio of 23.27, a PEG ratio of 2.08 and a beta of 0.13.

Haleon (NYSE:HLN) last issued its earnings results on Saturday, February 14th. The company reported $6.32 earnings per share for the quarter. The company had revenue of $3.65 billion during the quarter. On average, equities analysts anticipate that Haleon PLC Sponsored ADR will post 0.56 EPS for the current fiscal year.

Wall Street Analyst Weigh In

HLN has been the subject of a number of research reports. Wall Street Zen raised Haleon from a “hold” rating to a “buy” rating in a research report on Saturday, March 21st. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Haleon in a research report on Thursday, April 30th. Finally, Argus raised Haleon to a “strong-buy” rating in a research report on Tuesday, March 17th. Two equities research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Haleon has a consensus rating of “Moderate Buy”.

About Haleon

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.